Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 19 Similar Profiles
Therapeutics Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Androgens Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Sarcoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2016

Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy

Huang, W. & Ryan, C.

National Institutes of Health


Project: Research projectResearch Project--Cooperative Agreements

Blood Vessels

Research Output 1998 2017

  • 3804 Citations
  • 32 h-Index
  • 81 Article
  • 1 Chapter
  • 1 Review article
8 Citations

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

Heinrich, M. C., Rankin, C., Blanke, C. D., Demetri, G. D., Borden, E. C., Ryan, C. W., von Mehren, M., Blackstein, M. E., Priebat, D. A., Tap, W. D., Maki, R. G., Corless, C. L., Fletcher, J. A., Owzar, K., Crowley, J. J., Benjamin, R. S. & Baker, L. H. Jul 1 2017 In : JAMA oncology. 3, 7, p. 944-952 9 p.

Research output: Research - peer-reviewArticle

Gastrointestinal Stromal Tumors
Imatinib Mesylate

Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma

Ryan, C. W. Jan 1 2017 In : Journal of Oncology Pharmacy Practice. 23, 1, p. 43-55 13 p.

Research output: Research - peer-reviewReview article

Renal Cell Carcinoma
Standard of Care
2 Citations

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): An international, multicentre, open-label, randomised phase 3 trial

Tap, W. D. , Papai, Z. , Van Tine, B. A. , Attia, S. , Ganjoo, K. N. , Jones, R. L. , Schuetze, S. , Reed, D. , Chawla, S. P. , Riedel, R. F. , Krarup-Hansen, A. , Toulmonde, M. , Ray-Coquard, I. , Hohenberger, P. , Grignani, G. , Cranmer, L. D. , Okuno, S. , Agulnik, M. , Read, W. , Ryan, C. W. & 8 others Alcindor, T., del Muro, X. F. G., Budd, G. T., Tawbi, H., Pearce, T., Kroll, S., Reinke, D. K. & Schöffski, P. 2017 (Accepted/In press) In : The Lancet Oncology.

Research output: Research - peer-reviewArticle

TH 302
61 Citations

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial

Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., Lusk, C. M., Oberg, S. & George, D. J. Mar 1 2016 In : The Lancet Oncology. 17, 3, p. 378-388 11 p.

Research output: Research - peer-reviewArticle

Clear-cell metastatic renal cell carcinoma
Disease-Free Survival

Metastatic renal cell carcinoma without evidence of a renal primary

Costantino, C., Thomas, G. V., Ryan, C., Coakley, F. V. & Troxell, M. L. Jan 1 2016 In : International Urology and Nephrology. 48, 1, p. 73-77 5 p.

Research output: Research - peer-reviewArticle

Renal Cell Carcinoma
MART-1 Antigen
Adrenal Glands